Science & Enterprise subscription

Follow us on Twitter

  • The Federal Reserve, the U.S. central bank, released statistics showing in April 2020, manufacturing output dropped… https://t.co/q390P26pNf
    about 2 days ago
  • New post on Science and Enterprise: Infographic – Largest Ever U.S. Manufacturing Decline https://t.co/WkZSpIfnoj #Science #Business
    about 2 days ago
  • Two companies are using deep learning and virtual reality to design treatments for Covid-19 infections, attacking a… https://t.co/7K5to9yzvX
    about 2 days ago
  • New post on Science and Enterprise: Covid-19 Therapies Designed with Virtual Reality, A.I. https://t.co/4DK0JUeOiF #Science #Business
    about 2 days ago
  • A spin-off company from a university engineering lab received funds to build a device that efficiently splits water… https://t.co/nm0ArWQ3E3
    about 3 days ago

Please share Science & Enterprise

Covid-19 Antibody Therapy Prepares for Trial

Cattle

A biotechnology company producing synthetic antibodies in cattle, without human blood, to treat Covid-19 infections is advancing the therapy toward a clinical trial. . . . → Read More: Covid-19 Antibody Therapy Prepares for Trial

Retina Implant, Stem Cell Studies Set for Space Station

International Space Station

A company providing laboratory modules for biomedical research on the International Space Station received funding from NASA for three new projects. . . . → Read More: Retina Implant, Stem Cell Studies Set for Space Station

Synthetic DNA Studied for Mass Data Storage

DNA illustration

An industry-academic consortium received a U.S. government contract to develop coded synthetic polymer chemicals like DNA for reliably storing massive amounts of data. . . . → Read More: Synthetic DNA Studied for Mass Data Storage

A.I., Robotics Studied for Military Trauma System

Medevac training in Afghanistan

Medical and robotics labs at two universities in Pittsburgh are developing a portable, autonomous trauma care device to stabilize wounded military service people in the field. . . . → Read More: A.I., Robotics Studied for Military Trauma System

Platform to Integrate Robotics, Synthetic Biology, A.I.

Microbes

Two companies are developing a new model for a cloud-based platform that makes possible automated collaborative research with artificial intelligence in synthetic biology. . . . → Read More: Platform to Integrate Robotics, Synthetic Biology, A.I.

Zika Vaccine Clinical Trial Underway

The first of a series of clinical trials testing inactivated Zika particles as a vaccine to protect against the live Zika virus is recruiting participants. . . . → Read More: Zika Vaccine Clinical Trial Underway

Health Agency Funds Drug-Resistant Bacteria R&D

Biomedical Advanced Research and Development Authority, or BARDA, signed agreements worth $67 million to develop new treatments and diagnostics for urgent drug-resistant infections. . . . → Read More: Health Agency Funds Drug-Resistant Bacteria R&D

Influenza A Therapy Shown Working in Trial

Electron-microscope image of the 2009 H1N1 influenza virus (CDC.gov)

5 October 2015. A clinical trial testing a synthetic antibody designed to treat influenza A shows the treatment is effective in reducing the spread of flu viruses in humans. Visterra Inc., the therapy’s designer, also received a contract valued as much as $204.5 million . . . → Read More: Influenza A Therapy Shown Working in Trial

Regeneron to Develop Antibody Therapy for Ebola

Scanning electron micrograph shows Ebola virus budding on monkey kidney cells (Defense.gov)

21 September 2015. Regeneron Pharmaceuticals Inc. received a contract from the U.S. Department of Health and Human Services to develop an engineered antibody designed to treat Ebola infections. The initial $17 million contract from HHS’s Biomedical Advanced Research and Development Authority . . . → Read More: Regeneron to Develop Antibody Therapy for Ebola

Ebola-Marburg Vaccine Development, Testing Contract Awarded

Ebola health care workers in Guinea (European Commission-ECHO/USIAD)

31 October 2014. A biodefense unit of the U.S. Department of Defense awarded a contract to vaccine maker Profectus BioSciences Inc. for development and testing of a vaccine protecting against the two major Ebola strains and related Marburg viruses. The $9.5 million contract with the . . . → Read More: Ebola-Marburg Vaccine Development, Testing Contract Awarded